Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

This bill requires New Jersey hospitals to add fentanyl and xylazine testing to routine urine drug screenings for patients. It applies to all general acute care hospitals licensed under state law that conduct such screenings for patient diagnosis. If fentanyl or xylazine is detected, hospitals must report de-identified results to the Department of Health. The law aims to improve patient treatment during overdoses and provide state health data on these dangerous substances, which are increasingly found in street drugs.